Randomised Study Comparing the Use of Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Tanta University1 site in 1 country100 target enrollmentApril 1, 2016

ConditionsColonic Diseases

InterventionsPropofol Dexmedetomidine

DrugsPropofol Dexmedetomidine

Overview

Phase: Phase 3
Intervention: Propofol
Conditions: Colonic Diseases
Sponsor: Tanta University
Enrollment: 100
Locations: 1
Primary Endpoint: Number of patients with adequate sedation
Last Updated: 8 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Detailed Description

Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy

Registry

clinicaltrials.gov

Start Date

April 1, 2016

End Date

April 1, 2020

Last Updated

8 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Tanta University

Responsible Party

Principal Investigator

Sherief Abd-Elsalam

Principle investigator

Tanta University

Eligibility Criteria

Inclusion Criteria

•aged 25-45 years,
•ASA class I or II,
•who are scheduled for elective outpatient colonoscopy

Exclusion Criteria

•refused to give informed consent
•if they had known hypersensitivity to the used drugs
•patients with morbidly obese patients
•patients with increased risk for airway obstruction as obstructive sleep apnea,
•Liver diseases

Arms & Interventions

• Propofol Group

propofol 1.5 mg/kg slow intravenously, followed by maintenance dose of 0.5 mg/kg/h throughout the procedure..

Intervention: Propofol

• Dexmedetomidine Group

dexmedetomidine 1 ug/kg over 10 minutes as a bolus dose followed by continuous infusion at a dose of 0.5 ug/kg/h as maintenance dose throughout the procedure

Intervention: Dexmedetomidine